December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Allogeneic CAR T-cell therapy with ALLO-715 (anti-BCMA) and ALLO-647 (anti-CD52) was well tolerated and showed promising activity in heavily pretreated patients with relapsed/refractory multiple myeloma.